LCLAT1 and cardiac hypertrophy: It has been reported that ALCAT1-mediated CL pathological remodeling can accelerate CL oxidation and reduce CL content in models of myocardial hypertrophy, heart failure, diabetes, aging, obesity, and other diseases [16,17,19,20,21].